Navigation Links
Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
Date:11/7/2007

ent expected in the first quarter of 2008."

Nastech's pipeline, technology and opportunities remain strong with multiple products currently in Phase 2 clinical testing. Earlier this quarter, the company announced initiation of two phase 2 programs, one with PYY for obesity and the other with insulin to treat type 2 diabetes.

In February 2006, Nastech and P&G entered into a development and commercialization collaboration for teriparatide nasal spray as an investigational product. During the collaboration, P&G completed two clinical studies using teriparatide nasal spray: one evaluating the pharmacokinetic profile in healthy normal subjects, and the other demonstrating the response of bone turnover markers. These studies, in addition to the non-clinical work completed, demonstrate that Nastech's patented nasal spray formulation delivers teriparatide to the patient's blood, causes a response in bone turnover markers and was well-tolerated. Nastech believes that these data support the continued development of the product.

Nastech expects to recognize approximately $5.5 million in revenue in the fourth quarter due to termination of the agreement.

Conference Call and Webcast Information

Nastech management will host a conference call to discuss its development plans for teriparatide nasal spray. The call is scheduled for 8 a.m. EST/5 a.m. PST today, Wednesday, Nov. 7. To participate in the live conference call, U.S. callers should dial (866) 510-0711, and international callers should dial (617) 597-5379. The access code for the live conference call is 61597824. To access the 24-hour telephone replay, U.S. callers should dial (888) 286-8010, and international callers should dial (617) 801-6888. The access code for the replay is 80585364.

Alternatively, one can log on to http://www.nastech.com to access a live Webcast or the subsequent 30-day archive. Please connect to the Investor section
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
2. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
3. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...wswire-FirstCall/-- CryoLife,Inc. (NYSE: CRY ),ani...tissueprocessingcompany,announcedtodaythatitissche...ualHealthCareConferenceatTheNewYorkPalaceHotelonDe...hiefexecutiveofficerofCryoLife,Inc.,willprovideaco...ntsandhostaquestionandanswersessionat4:30p.m.Easte...
(Date:11/23/2009)....23/PRNewswire-FirstCall/--WoundManagementTechnolo...oviderofspecialtymedicalproducts,announcedthatitha...ehensivemanagementbusinessupdatetoillustratethedev...alesincreased33.5%to$102,926vs.Q32008salesof$77,08...o$3,327,892vs.Q32008shareholderequityof$(321,257) ...
(Date:11/23/2009)...23/PRNewswire-FirstCall/--Pharmasset,Inc.(Nasdaq: ...byitspartnerRoche(SWX:ROG.VX;RO.S,OTCQX:RHHBY),wil...theongoingphase2btrialofRG7128,afirst-in-classnucl...ronichepatitisCvirus(HCV)infection.Thedecisionwasr...toringCommittee(DMC)ofallavailablesafetydatafromth...
Breaking Medicine Technology:CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Children Uniting Nations Russell Simmons Mos Def David Archuleta Terrence Howard Gabrielle Union Vivica Fox Elise Neal and Shawn King Visit 48163 1Children Uniting Nations Russell Simmons Mos Def David Archuleta Terrence Howard Gabrielle Union Vivica Fox Elise Neal and Shawn King Visit 48163 2RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 1RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 2RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 3RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 4RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 5RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 6CVS Caremark Ranks Among 50 Best Fertility and Adoption Friendly Workplaces in America 48156 1CVS Caremark Ranks Among 50 Best Fertility and Adoption Friendly Workplaces in America 48156 2CVS Caremark Ranks Among 50 Best Fertility and Adoption Friendly Workplaces in America 48156 3
... an emerging,research-based pharmaceutical company...ation (FDA) has granted Orphan Drug Designation to...tment of chronic lymphocytic,leukemia (CLL). A Pha...ic,in Rochester, Minnesota where researchers are s...henon E in CLL patients., "The FDA Orphan Drug De...
...a,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced...inical trial with AZ-004 (Staccato(R) loxapine).,A...eloped for the treatment,of acute agitation in pat...za believes the novel, non-invasive nature and rap...inhaled loxapine administration via the,Staccato s...
Other Medicine Technology:Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6
(Date:11/23/2009)...lation of arsenic compounds appears to cause oxida...ity, according to a new study published online Nov...stitute . , Although biomethylation was once bel...ught to enhance its toxicity and potentially its c...c biomethylation in oxidative DNA damage in mice, ...
(Date:11/23/2009)...s saw their odds drop by 63 percent with moderate-...ov. 23 (HealthDay News) -- Moderate-to-high intens...ay help reduce stroke risk in older men but not in...d almost 3,300 men and women, average age 69, in M...uring that time, there were 238 strokes among the ...
(Date:11/23/2009)...artnershipswithMinorityBanksin Washington D.C.... S.C. IntendedtoSpurEconomicGrowthandRevitalizati...ire/--DaVita,thenation,sleadingproviderofdialysiss...heAnacostiacommunityfora$1millioninvestmentinIndus...oritycommunities. ,, DaVita,sinvestmentinWashin...
(Date:11/23/2009)...LLAS,Nov.23/PRNewswire/-- ,, WHAT: ,, The...erylCompanies, thenation,sleadinghealthcareexclus...tivelyreachconsumersineverygenerationwithapositive...erCEOofMinuteClinic,thisWebinarwillsupplementHowe,...nalPerspective,"whichdiscusseshowconsumerswillulti...
(Date:11/23/2009)...WYORK,Nov.23/PRNewswire/--Howistheeconomyaffecting...mp;SaatchiWellnessonWellness&theEconomy,theeco...ftsfromahealthylifestyleofexerciseanddiettoonethat...mate. ,, Thesurvey,smostdramaticfindingwasthech...romatraditionalfocusonhealthandwellbeingtotoday,sm...
Breaking Medicine News(10 mins):Health News:Vigorous Exercise Cuts Stroke Risk for Men, Not Women 2Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 2Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 4Health News:Tips to Improve Healthcare Customer Service Across All Generations 2Health News:Being Well Is About Reinvention - Not Health 2Health News:Being Well Is About Reinvention - Not Health 3
...vation Management Group,Inc. (IMG) announced today...low cost, full screen magnification software. Most... designed for individuals who have extreme visual,...riced within the reach of the average computer use...
...it National,Patient Advocate Foundation (NPAF), re...ted nationally in more than a decade through our,d...Foundation (PAF),continues to routinely receive in...g and chronic conditions, continue to,seek informa...
...sed wisely and in the right patients, experts say ...h Friday,s announcement of almost $5 billion to be...by the now-withdrawn painkiller Vioxx, the drug,s ...he focus back on the medications once again. , Cox...
...nome Sciences,Inc. (Nasdaq: HGSI ) announced toda...or Focus Conference will be webcast and may be acc....newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) A m... Investors interested in listening to the live web...
...Nasdaq: MASI ),the inventor of Pulse CO-Oximetry ...imetry, announced today that the Pricing Committee...stockholder rights plan. "This plan is designed t...ce to all stockholders or are otherwise,not in the...
...ng-Plough,Corporation (NYSE: SGP ) will provide a... Bertolini, executive vice president and chief fin...are Conference in Phoenix,Ariz., on Nov. 13, 2007,...-Plough corporate Web site, http://www.schering-pl...
Other Medicine News:Health News:IMG Announces an Affordable Full Screen Software Magnifier for Home and Business Users 2Health News:National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs) 2Health News:Vioxx Settlement Puts Painkillers Back in the Spotlight 2Health News:Vioxx Settlement Puts Painkillers Back in the Spotlight 3Health News:Vioxx Settlement Puts Painkillers Back in the Spotlight 4Health News:Masimo Corporation Adopts Stockholder Rights Plan 2Health News:Masimo Corporation Adopts Stockholder Rights Plan 3
No.12 Surgical Blade
Standard
Rib Back
BD Beaver Phaco slit blade
Medicine Products: